<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652739</url>
  </required_header>
  <id_info>
    <org_study_id>Lycopene and lichen planus</org_study_id>
    <nct_id>NCT04652739</nct_id>
  </id_info>
  <brief_title>Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus</brief_title>
  <official_title>Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus (A Randomized Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nourhan M.Aly</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alexandria</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effect of oral lycopene and systemic steroids in&#xD;
      the treatment of erosive oral lichen planus and compare between the two therapeutic&#xD;
      modalities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty erosive lichen planus patients were recruited and randomly assigned in one of two&#xD;
      groups, the test (lycopene) and control (corticosteroids) group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">March 10, 2019</completion_date>
  <primary_completion_date type="Actual">March 3, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment was conducted using Visual Analogue Scale (VAS)</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Patients were instructed to mark a 10 cm line at a point equivalent to their present pain. The score was determined by measuring the distance in mm on the line from the &quot;no pain&quot; anchor to the patient's mark, providing a range of scores from 0-100. A Pain-free experience was scored zero, while the worst pain was scored 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion size assessment</measure>
    <time_frame>up to 5 months</time_frame>
    <description>Assessment of OLP lesions was performed using the Thongprasom et al. scoring index where:&#xD;
Score 0: No lesion/Normal mucosa.&#xD;
Score 1: Mild white striae only.&#xD;
Score 2: White striae with erythematous area &lt;1cm².&#xD;
Score 3: White striae with erythematous area &gt;1cm².&#xD;
Score 4: White striae with erosive area &lt;1cm².&#xD;
Score 5: White striae with erosive area &gt;1cm².&#xD;
Scores from different oral sites were added to give a final score for every patient from 0-50.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Erosive Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Lycopene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lycopene Softgel, 10 Mg</intervention_name>
    <description>Patients were given 10 mg of lycopene softgel capsules once daily for two months. The active ingredient in each capsule consists of 10 mg lycopene from natural tomato extract.</description>
    <arm_group_label>Lycopene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Patients were given 40 mg of prednisolone tablets once daily in the morning for one month, afterwards, the dose was tapered along the following month. Incremental reduction of 10 mg each week for the first three weeks, followed by 5 mg reduction in the last week, was the tapering protocol in this study. The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).</description>
    <arm_group_label>Corticosteroids</arm_group_label>
    <other_name>Corticosteroids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Erosive oral lichen planus patients with severe and extensive painful erythematous,&#xD;
             erosive and/ or ulcerative lesions who are in need for systemic corticosteroid therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant females and smokers.&#xD;
&#xD;
          -  Patients suggestive of having lichenoid contact/drug reactions.&#xD;
&#xD;
          -  Patients suffering from any systemic disease as diabetes, liver disease, renal&#xD;
             disease, any other autoimmune or collagen disease.&#xD;
&#xD;
          -  Lesions showing histological features of dysplasia.&#xD;
&#xD;
          -  Patients with skin lichen planus lesions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aliaa A Bedeir, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Dentistry, Alexandria University, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Azza M Zaki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Dentistry, Alexandria University, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabah A Mahmoud, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Alexandria University, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Dentistry, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21512</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992 Nov;21(10):456-8.</citation>
    <PMID>1460584</PMID>
  </reference>
  <reference>
    <citation>Gobbo M, Rupel K, Zoi V, Perinetti G, Ottaviani G, Di Lenarda R, Bevilacqua L, Woo SB, Biasotto M. Scoring systems for Oral Lichen Planus used by differently experienced raters. Med Oral Patol Oral Cir Bucal. 2017 Sep 1;22(5):e562-e571. doi: 10.4317/medoral.21833.</citation>
    <PMID>28809373</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alexandria</investigator_affiliation>
    <investigator_full_name>Nourhan M.Aly</investigator_full_name>
    <investigator_title>Assistant Lecturer of Dental Public Health</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Lycopene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

